Finanzwire Finanzwire
Basculer en Français
10337 Companies
214557 Keywords
144382 Articles
113645 Press releases
Headlines Articles Press releases INNATE PHARMA Remove
  1. Home
  2. Companies
  3. INNATE PHARMA
Finanzwire
Basculer en Français
Headlines Articles Press releases

News

  • PRESS RELEASE

    published on 06/17/2024 at 07:00, 1 year 10 months ago

    Inside Information / Other news releases

    Innate Pharma shares updated results from the Sanofi developed blood cancer Phase 1/2 SAR443579/IPH6101 trial, showing promising clinical efficacy and safety in patients with R/R AML
    Sanofi Innate Pharma Blood Cancer NK Cell Engager Phase 1/2 Trial
    Logo of INNATE PHARMA
  • BRIEF

    published on 05/28/2024 at 07:05, 1 year 11 months ago

    Innate Pharma announces its participation in upcoming investor conferences

    Biotechnology Investor Conferences Immunotherapy Health Innate Pharma
  • BRIEF

    published on 05/23/2024 at 22:05, 1 year 11 months ago

    Results of the Combined General Meeting of Innate Pharma

    Voting Results Supervisory Board General Assembly Innate Pharma
  • PRESS RELEASE

    published on 05/23/2024 at 22:00, 1 year 11 months ago

    Inside Information / Other news releases

    Innate Pharma announces the voting results of its 2024 AGM. Quorum at 44.92%. Re-election of two Supervisory Board members. Details available on company's website
    Voting Results Supervisory Board Quorum 2024 AGM Innate Pharma
    Logo of INNATE PHARMA
  • BRIEF

    published on 05/21/2024 at 07:05, 1 year 11 months ago

    Clarification on the status of SAR443579 treatment by Innate Pharma

    FDA Sanofi Innate Pharma SAR443579 Fast Track
Previous page
1 ... 6 7
Accesswire
  • Published on 05/02/2026 at 21:00, 8 hours 9 minutes ago

    GECC Subsidiary Provides Update on its Lawsuit for Damages Against the Lender of the Atmosphere Project

  • Published on 05/02/2026 at 01:30, 1 day 3 hours ago

    Uraniumx Reports Strong Financial Position Ahead of Spring Drill Program

  • Published on 05/02/2026 at 00:50, 1 day 4 hours ago

    CoTec Announces Annual Stock Option, Restricted Share Unit And Deferred Share Unit Grants

  • Published on 05/02/2026 at 00:00, 1 day 5 hours ago

    Redwood AI Announces Enhanced AI Models, Increasing Evaluated Chemical Reactions Following Preliminary Results from UBC Collaboration

  • Published on 05/02/2026 at 00:00, 1 day 5 hours ago

    Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies

View all ACCESSWIRE
EQS Group
  • Published on 05/03/2026 at 04:45, 23 minutes ago

    GWM Unveils World-Class Safety & Testing Facilities: Safety Built on Data, Not Hype

  • Published on 05/02/2026 at 15:35, 13 hours 33 minutes ago

    Ecuador's banana sector renews labor agreement, with jobs meeting global standards

  • Published on 05/01/2026 at 19:23, 1 day 9 hours ago

    Fuller, Smith & Turner PLC: Transaction in own shares

  • Published on 05/01/2026 at 18:40, 1 day 10 hours ago

    Holding(s) in Company

  • Published on 05/01/2026 at 17:47, 1 day 11 hours ago

    Key Figures 30.04.2026

View all EQS
Les Echos
  • Published on 04/30/2026 at 20:00, 2 days 9 hours ago

    AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue

  • Published on 04/30/2026 at 19:16, 2 days 9 hours ago

    AXA announces the results of its Shareholders' Meeting

  • Published on 04/30/2026 at 19:00, 2 days 10 hours ago

    Capital increase through exercise of subscription rights

  • Published on 04/30/2026 at 18:10, 2 days 10 hours ago

    Minutes of the Combined General Meeting held on April 30, 2026

  • Published on 04/30/2026 at 18:00, 2 days 11 hours ago

    TF1 Q1 2026 results - Press release

View all LES ECHOS COMFI WIRE

With finanzwire.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

Finanzwire

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

© 2026 Finanzwire

Contact Authors Cookies policy Terms and conditions Privacy policy